MurepavadinAntibacterial peptidomimetic
Murepavadin targets an outer-membrane protein of Pseudomonas aeruginosa. Its development illustrates why antibacterial activity and safety at the required exposure must be evaluated together.
What is Murepavadin?
Murepavadin is a cyclic peptidomimetic developed to target Pseudomonas aeruginosa, rather than a broad range of bacteria.
How it works
It acts on LptD, a protein involved in assembly of the organism’s outer membrane.
Effects studied
What does the evidence show?
Antibacterial pharmacology and clinical development; archived references retained
A focused bacterial target
Murepavadin is a cyclic peptidomimetic developed to act on LptD, a protein involved in assembling the outer membrane of Pseudomonas aeruginosa. This makes its approach more targeted than the broad description “kills bacteria” suggests. The organism must be identified and the infection understood.
Why narrow targeting can be interesting
A treatment directed at a particular pathogen may be valuable when that organism is difficult to treat. Laboratory activity helps identify this possibility. It does not establish clinical success, because drug exposure at the infection site and the patient’s condition also influence the outcome.
The development history includes a safety problem
The archived account describes kidney-safety concerns during intravenous development. These concerns need to be weighed alongside the antibacterial rationale. The exact trial data and current programme status still require source-level review before a detailed clinical conclusion can be drawn.
A different route is a new question
Delivery to the lungs could change both local exposure and systemic toxicity, but evidence is needed to establish whether it resolves the earlier safety problem. The assessment depends on the infection, route, bacterial response and effects on the patient. Calling murepavadin promising or unsuccessful without those details says little about its possible use.
Safety & status
The archived account includes kidney-safety concerns during intravenous development. Those details require further source-level review; a different delivery route cannot be assumed to remove the problem.
Country and product status
Country-specific product availability and authorisation require a separate current check.
Frequently asked questions
Is it intended for every resistant bacterial infection?
No. Its target and development focus are specific to Pseudomonas aeruginosa.
Would inhaled delivery automatically solve kidney-safety concerns?
No. Changing the route changes exposure, but any safety advantage needs to be demonstrated.
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Murepavadin · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
- Murepavadin · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.